Atara Biotherapeutics Board Shake-Up: Sales Trigger

🚀 Battle Card: Atara Biotherapeutics, Inc.

• Greg Ciongoli, Chair of the Board of Directors · 🔗 LinkedIn

• New board leadership under Greg suggests a refocused push on Ebvallo milestones and BLA progress, making this Atara Biotherapeutics sales trigger a prime moment to pitch regulatory and cost optimization solutions. → Source

• Maximizing value from Ebvallo milestones and royalties

• Securing FDA approval of resubmitted BLA within a tighter budget

• Primary: Regulatory Intelligence Platform → Accelerate BLA review & approval timelines

• Expansion: Operational Cost Benchmarking → Identify $ savings and optimize R&D spend

• HQ: Thousand Oaks, CA

• Employees: ≈ 23

• Rev: ≈ $10 M

• Website: https://www.atarabio.com/

🤼 Competitive Intel

• Parexel — Regulatory Consulting
• Unique edge: Global FDA submission expertise for advanced therapies
• Evaluated by Board Chair & VP R&D

• IQVIA — Clinical Development
• Unique edge: Integrated data analytics & trial ops for cell therapy
• Evaluated by VP Clinical for trial acceleration

• Lonza — Cell Therapy Manufacturing
• Unique edge: Scalable allogeneic production capabilities
• Evaluated by COO for cost-effective GMP supply

✅ Do-Now Checklist

Next Step

🧠 Copy My Prompt for Personalized Cold Outreach

────────────────────────────
✏️ YOUR COMPANY
────────────────────────────
OUR_COMPANY   = ❑❑
OFFER_BRIEF   = ❑Regulatory Intelligence Platform❑
PROOF_METRIC  = ❑≈ 30% faster approval times❑
CTA_STYLE     = ❑quick_call | case_study❑
TONE          = ❑friendly | punchy❑

────────────────────────────
📌 TARGET COMPANY
────────────────────────────
NAME        = Greg
COMPANY     = Atara Biotherapeutics, Inc.
DEPT        = Board of Directors
SIZE        = 23
BOTTLENECK  = Maximizing value from Ebvallo milestones and royalties
EVENT       = Changes to Board Leadership
DETAIL      = Greg Ciongoli assumes Chair of the Board
PAIN        = Securing FDA approval of resubmitted BLA within a tighter budget
SRC         = http://cts.businesswire.com/ct/CT?id=ftfLlWd9aZbF2NXfwppam3Bd664=&newsLang=en&newsId=20250903414165&div=41152219
SIM_CO      = ≈ TBD
WIN_METRIC  = ≈ TBD
NEXT_SIZE   = ≈ TBD
EMP_EST     = ≈ 23
REV_EST     = ≈ $10M

────────────────────────
TASK FOR CHATGPT
────────────────────────
Role: “NewsletterForLeads SDR-Assist”.

Validate any ≈ guesses via SRC.

EMAIL  (keep breaks):
Subject: 23-person Board of Directors

Greg—noticed your Board of Directors team is ≈ 23.

That’s when Maximizing value from Ebvallo milestones and royalties slows growth.

We helped ≈ TBD fix this with Regulatory Intelligence Platform.

Result: ≈ TBD.  
Quick call?

PS—next bottleneck hits ≈ TBD.

DM ≤45 words, TONE:
Saw your post about Greg Ciongoli assumes Chair of the Board — Securing FDA approval of resubmitted BLA within a tighter budget.  
Regulatory Intelligence Platform. ≈ 30% faster approval times.  
Quick chat?